Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Raised to “Hold” at Wall Street Zen

Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Get Valion Bio Inc. Common Stock alerts:

Get Our Latest Stock Report on Valion Bio, Inc. Common Stock

Valion Bio, Inc. Common Stock Price Performance

NASDAQ VBIO opened at $2.77 on Friday. The business has a fifty day moving average price of $7.63 and a 200 day moving average price of $16.98. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.86 and a current ratio of 1.11. The company has a market cap of $2.47 million, a P/E ratio of -0.43 and a beta of 1.79. Valion Bio, Inc. Common Stock has a one year low of $2.70 and a one year high of $80.19.

About Valion Bio, Inc. Common Stock

(Get Free Report)

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.

Read More

• Five stocks we like better than Valion Bio, Inc. Common Stock
• AI Token Costs Are Changing the Hardware vs. Software Debate
• 3 ETFs That Could Move as Rate Expectations Shift
• 3 Stocks With September Catalysts Investors Shouldn’t Ignore
• Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains

Receive News & Ratings for Valion Bio Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valion Bio Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.